Medicare Drug Benefit Unlikely To Pass This Year, Lobbyist Steelman Says
Executive Summary
Congress is "very unlikely" to pass a Medicare drug benefit bill this year, Steelman Health Strategies President Deborah Steelman told a healthcare conference sponsored by the Schwab Washington Research Group May 22 in Washington, D.C.
You may also be interested in...
Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research
Pharmaceutical companies would be required to pay a "return on investment fee" from profits on drugs that benefited from federal research funding under a Medicare drug benefit proposal outlined May 26 by Rep. Thomas (R-Calif.) and Sen. Wyden (D-Ore.).
Thomas/Wyden Medicare Rx Plan Has Royalty On Federally Funded Research
Pharmaceutical companies would be required to pay a "return on investment fee" from profits on drugs that benefited from federal research funding under a Medicare drug benefit proposal outlined May 26 by Rep. Thomas (R-Calif.) and Sen. Wyden (D-Ore.).
Maine Rx Pricing Law Seeks FSS-Level Prices By October 2001
The "Maine Rx" discount law seeks Federal Supply Schedule-level rebates for prescriptions filled in Maine by October 2001.